2013年

Glaucocalyxin A inhibits platelet activation and thrombus formation preferentially via GPVI signaling pathway. Li W, Tang X, Yi W, Li Q, Ren L, Liu X, Chu C, Ozaki Y, Zhang J, Zhu L. PLoS One. 2013;8(12):e85120.

Kanemaru K, Nishiyama Y, Yoshioka H, Satoh K, Hashimoto K, Hanihara M, Horikoshi T, Ozaki Y, Kinouchi H. In-stent thrombosis after carotid artery stenting despite sufficient antiplatelet therapy in a bladder cancer patient. J Stroke Cerebrovasc Dis. 2013;22(7):1196-200.

Kimura Y, Takano K, Satoh K, Aida K, Kobayashi T, Ozaki Y. Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of Healthy Individuals. Clin Appl Thromb Hemost. 2013;20(6):629-636

Satoh K, Hirayama T, Takano K, Suzuki-Inoue K, Sato T, Ohta M, Nakagomi J, Ozaki Y.　VacA, the vacuolating cytotoxin of Helicobacter pylori, binds to multimerin 1 on human platelets. Thromb J. 2013;11:23.

Wannemacher KM, Jiang H, Hess PR, Shin Y, Suzuki-Inoue K, Brass LF. An expanded role for semaphorin 4D in platelets includes contact-dependent amplification of Clec-2 signaling. 　J Thromb Haemost. 2013;11:2190-3.

Ozaki Y, Suzuki-Inoue K, Inoue O. Platelet receptors activated via mulitmerization: glycoprotein VI, GPIb-IX-V, and CLEC-2.　J Thromb Haemost. 2013;11 Suppl 1:330-9.

長田誠、井上克枝、井上修、尾崎由基男．　血小板 CLEC-2 のリンパ管発生での役割と臨床応用　臨床病理 2013;61:318-27

井上克枝　血栓性疾患―薬効薬理と病態生理に基づいた治療戦略の展開　キーワード　「CLEC-2 とポドプラニン」　カレントテラピー　31: 93, 2013

第24回　国際血栓止血学会（アムステルダム/オランダ）
VacA, the vacuolating cytotoxin of Helicovactor pylori, binds to multimerin1 associated with platelet membranes. 佐藤金夫
A role of CLEC-2 in tumor growth and metastasis. 白井俊光

第35回　日本血栓止血学会（山形）
血小板活性化受容体ＣＬＥＣ-2の癌の血行性転移、リンパ行性転移、増殖における役割　白井俊光

第90回　日本生理学会大会（東京）
血小板活性化受容体ＣＬＥＣ-2のリンパ管新生、癌転移における役割　井上克枝

未登録